SCNI Scinai Net Sales Margin

Capacity restructuring and high fixed costs are currently limiting the operational efficiency of Scinai Immunotherapeutics (SCNI). Meanwhile, the company is attracting leading NanoAbs researchers through a flexible corporate culture and RSUs. On the GURU.Markets platform, the net margin indicator demonstrates profit dynamics, where -81.60 reflects the metric's baseline. The development strategy is based on creating nanobodies for the therapy of psoriasis and infections.
Summary analytical data breakdowns for Scinai Immunotherapeutics (SCNI)

The operational efficiency of Scinai Immunotherapeutics (SCNI) is directly reflected in the dynamics of its net profit margin. This metric measures the share of net income in total revenue, demonstrating the business's real-time resilience. The current value of -81.60 confirms the critical dependence of capital on R&D expenditures. In the absence of commercial revenue, the negative trend on the chart highlights a high cash burn rate. This signals investment risks associated with the early stages of biologic drug trials.